Breast Invasive Lobular Carcinoma
Associated Genetic Biomarkers
NCI Definition: An infiltrating lobular adenocarcinoma of the breast. The malignant cells lack cohesion and are arranged individually or in a linear manner (Indian files), or as narrow trabeculae within the stroma. The malignant cells are usually smaller than those of ductal carcinoma, are less pleomorphic, and have fewer mitotic figures. 
Breast invasive lobular carcinomas most frequently harbor alterations in CDH1, PIK3CA, TP53, CCND1, and ERBB2 .
PIK3CA Mutation, CDH1fs, CDH1 Mutation, PIK3CA Codon 1047 Missense, and PIK3CA H1047R are the most common alterations in breast invasive lobular carcinoma .
There are 5 clinical trials for breast invasive lobular carcinoma, of which 5 are open and 0 are completed or closed. Of the trials that contain breast invasive lobular carcinoma as an inclusion criterion, 1 is early phase 1 (1 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open).
ER, ERBB2, and HER2 are the most frequent gene inclusion criteria for breast invasive lobular carcinoma clinical trials .
Imipramine, anastrozole, and cyclophosphamide are the most common interventions in breast invasive lobular carcinoma clinical trials.
Significant Genes in Breast Invasive Lobular Carcinoma
ERBB2 is altered in 12.05% of breast invasive lobular carcinoma patients .
ERBB2 is an inclusion eligibility criterion in 3 clinical trials for breast invasive lobular carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 status and breast invasive lobular carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.